

Financial Tear Sheet

Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

Stock Information

BCLI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Price	\$3.07
Change (%)	▲ 0.02 (0.66%)
Volume	30,033
52 Week Low	\$2.88
Market Cap	\$63,157,073
Rolling EPS	-0.42
PE Ratio	0
Shares Outstanding	20,707,237
Data as of 11/13/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

November 7, 2018

BRAINSTORM CELL THERAPEUTICS TO PRESENT AT NOVEMBER CLINICAL AND INVESTOR CONFERENCES

October 29, 2018

BRAINSTORM ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018 AND PROVIDES A CORPORATE UPDATE

October 17, 2018

BRAINSTORM TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON MONDAY, OCTOBER 29

SEC Filings

Filing Date	Form
10/29/18	10-Q
10/10/18	DEF 14A
09/28/18	EFFECT
09/28/18	424B1

Upcoming Events

BRAINSTORM CELL THERAPEUTICS - THIRD QUARTER 2018 EARNINGS CALL

October 29, 2018 8:30 a.m. ET

Primary IR Contact

Michael Rice

LifeSci Advisors LLC

E-mail: mrice@lifesciadvisors.com